Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7138MR)

This product GTTS-WQ7138MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7138MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14121MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ7909MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ6159MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ12091MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ12329MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ7396MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ8372MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ7690MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW